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PGE
2
is a lipid mediator abundantly produced in inflamed tissues that exerts relevant immunoregulatory functions. Dendritic cells
(DCs) are key players in the onset and shaping of the inflammatory and immune responses and, as such, are well known PGE
2
targets. By contrast, the precise role of human DCs in the production of PGE
2
is poorly characterized. Here, we asked whether
different ligands of Toll-like receptors (TLRs), a relevant family of pathogen-sensing receptors, could induce PGE
2
in human
DCs. The only active ligands were LPS (TLR4 ligand) and R848 (TLR7-8 ligand) although all TLRs, but TLR9, were expressed
and functional. While investigating the molecular mechanisms hindering the release of PGE
2
, our experiments highlighted so
far oversight differences in TLR signalling pathways in terms of MAPK and NF-𝜅B activation. In addition, we identified that the
PGE
2
-limiting checkpoint downstreamTLR3, TLR5, and TLR7 was a defect in COX2 induction, while TLR1/2 and TLR2/6 failed to
mobilize arachidonic acid, the substrate for the COX2 enzyme. Finally, we demonstrated the in vivo expression of PGE
2
by myeloid
CD11c+ cells, documenting a role for DCs in the production of PGE
2
in human inflamed tissues.
1. Introduction
PGE
2
is the predominant eicosanoid produced in inflamed
tissues and by growing tumors, with a major contribution
by infiltrating immune cells [1, 2]. Because PGE
2
promotes
vasodilatation and accumulation of proinflammatory cells,
it is generally recognized as a mediator of active inflam-
mation. However, by suppressing the production of some
proinflammatory cytokines, PGE
2
also limits nonspecific
inflammation and fosters the immune suppression associated
with chronic inflammation and cancer [1, 2]. Despite the fact
that PGE
2
targeting is easily done by common and effective
pharmaceutical agents (i.e., steroids and nonsteroid anti-
inflammatory drugs), an accurate understanding of PGE
2
regulation andmechanisms of action is crucial to fully deploy
the therapeutic potential of these drugs.
The inflammatory synthesis of PGE
2
is regulated by
three classes of enzymes: cytosolic phospholipase A
2
(cPLA
2
)
family members that mobilize arachidonic acid (AA) from
cellular membranes, cyclooxygenases (COX1 and COX2)
that convert AA into PGH
2
, and specific synthases account-
ing for the final conversion of PGE
2
[2]. While COX1 is
housekeeping gene governing homeostatic PGE
2
production,
COX2 is potently induced by proinflammatory stimuli [3]. In
inflammation, the rate of PGE
2
production largely depends
on the expression and activity of COX2, although it can
be affected by other factors such as local availability of AA
[2].
Dendritic cells (DCs) are professional antigen presenting
cells responsible for the activation of the adaptive immune
response [4] and also play a crucial role in the regulation
of inflammation [5, 6]. For doing this, DCs are equipped
with the vastest repertoire of pathogen-sensing receptor (pat-
tern recognition receptors, PRR) such as NOD-like recep-
tors, C-type lectin receptors, and Toll-like receptors (TLRs)
[7–10].
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Human TLRs are a family of type I transmembrane
proteins [11]. Upon microbial recognition, TLRs recruit a
specific set of adaptormolecules, such asMyD88 and TRIF, to
initiate downstream signal transduction pathways. MyD88 is
used by all TLRs except TLR3 and activates the transcription
factorNF-𝜅B andmitogen-activated protein kinases (MAPK)
to induce inflammatory cytokines. By contrast, TRIF is used
by TLR3 (and TLR4) and induces the secretion of type I
interferons and also some NF-𝜅B-depending genes [11, 12].
The TLR signalling cascades have been described using
murine cells from knockout animals or immortalized cell
lines of tumor origin. As a result, little is known about the
pathways and cellular responses activated by TLRs in human
primary cells.
Given the importance of PGE
2
in the orchestration of the
immune and inflammatory responses, we set out to dissect
the molecular mechanisms underlying its release by TLR-
specific ligands in human DCs.
2. Materials and Methods
2.1. Cell Preparation and Culture. Buffy coats were obtained
through the courtesy of the Centro Trasfusionale, Spedali
Civili, Brescia. Monocytes were purified from peripheral
blood mononuclear cells (PBMC) by immunomagnetic sep-
aration using anti-CD14-conjugated magnetic microbeads
(Miltenyi Biotec, Bergisch Gladbach, Germany). DCs were
differentiated from monocytes cultured for 6 days in tissue
culture plates in RPMI 1640 (Gibco, Life Technologies,
Carlsbad, CA, USA) supplemented with 10% heat-inactivated
fetal calf serum (FCS, Lonza Group, Switzerland), 2mM L-
glutamine, antibiotics (Gibco) (complete RPMI medium),
50 ng/mL GM-CSF, and 20 ng/mL IL-4 (ProSpec Techno-
gene, Israel) as previously described [13]. Myeloid DCs
(mDCs) were isolated using the CD1c (BDCA-1)+ Dendritic
Cell Isolation Kit (Miltenyi Biotec).
2.2. Reagents. DCs or mDCs (2 × 106 cells/mL) were stimu-
lated with the following TLR ligands: 100 ng/mL PAM
3
CSK
4
,
ligand for TLR1/2; 100 ng/mL FSL-1, ligand for TLR2/6;
25 𝜇g/mL Poly I:C, ligand for TLR3; 100 ng/mL Flagellin,
ligand for TLR5 (Bacillus subtilis); 5 𝜇g/mL Imiquimod,
ligand for TLR7; 5 𝜇g/mL R848, ligand for TLR7 and
TLR8; 6 𝜇g/mL CpG ODN 2216, ligand for TLR9 (all from
Invivogen, San Diego, California, USA); 100 ng/mL LPS,
ligand for TLR4 (Escherichia coli 055:B5; Sigma-Aldrich,
St. Louis, MO); and heat-killed Escherichia coli (specific
for TLR4; 1 : 10mDC/bacteria ratio, Invivogen). TLR ligand
concentrations used in the present paper were determined as
optimal for DCs stimulation by preliminary experiments and
previously published work by this group [13]. Where indi-
cated, 10 𝜇M arachidonic acid was added. U0126 (a MEK1/2
inhibitor), PD98059 (an ERK1/2 inhibitor), SB203580 (a p38
MAPK inhibitor), JNK Inhibitor II (a JNK inhibitor), and
BAY11-7082 (a NF-𝜅B inhibitor) were from Calbiochem (San
Diego, CA).
2.3. PGE2 and CXCL8 Determination. DCs were incubated
for 24 h with the indicated treatments. Cell-free supernatants
were harvested and PGE
2
production was measured by EIA
(Cayman Chemical) kit. Secreted CXCL8 was measured by
ELISA assay according to the manufacturer instructions
(R&D Systems, Minneapolis, MN, USA).
2.4. Real-Time PCR. RNAwas extracted in TRIzol, according
to the manufacturer’s instructions. After RNA purification,
samples were treated with DNase to remove contaminat-
ing genomic DNA (DNaseI amplification grade). Reverse
transcription was performed using random hexamers and
Superscript II RT. All reagents were from Invitrogen. The
iQ SYBR Green Supermix (Bio-Rad Laboratories Inc.,
Hercules, CA, USA) for quantitative real-time PCR was used
according tomanufacturer’s instructions. Reactions were run
in triplicate on an iCycler (Bio-Rad Laboratories Inc.) and
the generated products analysed by the iCycler iQ Optical
System Software (Version 3.0a, Bio-Rad Laboratories Inc.).
Gene specific primers were as follows: hHPRT (forward:
5󸀠-CCAGTAACAGGGGACATAAA-3󸀠, reverse: 5󸀠-CAC-
AATCAAGACATTCTTTCCAGT-3󸀠); hTLR1 (forward: 5󸀠-
CCTAGCAGTTATCACAAGCTCAAA-3󸀠, reverse: 5󸀠-TC-
TTTTCCTTGGGCCATTC-3󸀠); hTLR2 (forward: 5󸀠-CG-
TTCTCTCAGGTGACTGCTC-3󸀠, reverse: 5󸀠-CCTTTGGA-
TCCTGCTTGC-3󸀠); hTLR3 (forward: 5󸀠-AGTTGTCATCG-
AATCAAATTAAAGAG-3󸀠, reverse: 5󸀠-AATCTTCCAAT-
TGCGTGAAAA-3󸀠); hTLR4 (forward: 5󸀠-CTCCCCTG-
TACCCTTCTCACT-3󸀠, reverse: 5󸀠-CTCCCTGCCTTGAA-
TACCTTC-3󸀠); hTLR5 (forward: 5󸀠-GACACAATCTCGGC-
TGACTG-3󸀠, reverse: 5󸀠-GCCAGGAACATGAACATCAA-
3󸀠); hTLR6 (forward: 5󸀠-TGAAACAGTCTCTTTTGAGT-
AAATGC-3󸀠, reverse: 5󸀠-TCCATTTGGGAAAGCAGAGT-
3󸀠); hTLR7 (forward: 5󸀠-TTAACCAATTGCTTCCGTGTC-
3󸀠, reverse: 5󸀠-GGTGCCCACACTCAATCTG-3󸀠); hTLR8
(forward: 󸀠5-TGTGGTTGTTTTCTGGATTCAA-3󸀠, reverse:
5󸀠-GCTCGCATGGCTTACATGA-3󸀠); hTLR9 (forward: 5󸀠-
TGTGAAGCATCCTTCCCTGT-3󸀠, reverse: 5󸀠-GAGAG-
ACAGCGGGTGCAG-3󸀠). Gene expression was normalized
based on HPRT mRNA content.
2.5. SDS-PAGE and Western Blot. Following the designated
treatments, DCs were washed twice with PBS and lysed in L1
buffer (50mM Tris-HCl, pH 8.0; 2mM EDTA; 0.1% NP-40
and 10%glycerol) with inhibitors to separate cytoplasmic pro-
teins. Nuclear pellets were washed twice with L1 buffer with
inhibitors and then lysed in NP-40 Lysis buffer (50mM Tris-
HCl, pH 8.0; 250mM NaCl; 1mM EDTA; 0.1% NP-40; and
10%glycerol)with inhibitors. Total cell extractswere obtained
with NP-40 Lysis buffer. Equal amounts of cytoplasmic,
nuclear, or total extracts were analysed through 8–12% SDS-
PAGE followed by Western blotting with antibodies against
COX2 (mouse monoclonal, Cat. 160112, Cayman Chemical),
phospho-ERK1/2 (rabbit polyclonal, Cat. 9101, Cell Signalling
Technologies, Massachusetts, USA), phospho-p38 (rabbit
polyclonal, Cat. 9211, Cell Signalling), phospho-cPLA
2
(rabbit
polyclonal, Cat. 2831, Cell Signalling), phospho-MSK1 (rabbit
polyclonal, Cat. 9595, Cell Signalling), NF-𝜅B p65 (rabbit
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polyclonal, C-20 Cat. sc-372, Santa Cruz Biotechnology), 𝛽-
actin (mouse monoclonal, C-4 Cat. sc-44478, Santa Cruz
Biotechnology), and Lamin B (goat polyclonal, C-20 Cat.
sc-6216, Santa Cruz Biotechnology). Protein bands were
detectedwith SuperSignalWest Pico Chemiluminescent Sub-
strate (Pierce, Rockford, USA). Densitometric analysis was
performed using ImageJ (version 1.48) software package from
National Institutes of Health. Immunoblots were scanned as
JPEG images and the areas under the curves were measured
for each band and quantified. Data were normalized based on
𝛽-actin or Lamin B content.
2.6. Release of [14C] AA. DCs (6× 106/mL, in RPMI 1640, 10%
FCS) were labelled in Petriperm dishes with 0.125𝜇Ci/mL
[14C] AA (Amersham, Buckingham, UK) overnight.
At the end of the incubation, cells were washed twice and
resuspended inRPMI 1640 supplementedwith 0.2% fatty acid
free bovine serum albumin (Sigma). DCs were stimulated
for 3 h and the reaction was terminated by the addition of
2mL of chloroform/methanol/formic acid (1 : 2 : 0.2, v/v/v,
all from Sigma-Aldrich) followed by agitation. Then, 1mL of
water and 2mL chloroform were added. Chromatographic
separation of lipids was performed by evaporating the
organic phase under a stream of nitrogen, redissolving the
residue in chloroform, and loading the extract on silica gel
G plates (Merck, Darmstadt, Germany). Fatty acids were
separated by thin layer chromatography using hexane/ethyl
ether/formic acid (15 : 10 : 1, v/v/v, all from Sigma-Aldrich)
as a solvent system for 30min. AA position on TLC plates
was determined as comigration with commercially available
standard after exposure to iodine vapors. Autoradiography
of TLC plates was performed using a phosphoimaging
system (FLA 2000, Fuji). The results are expressed as
the percentage of radioactivity in the arachidonic acid
band on the total radioactivity recovered from each
lane.
2.7. Immunohistochemistry. Formalin-fixed paraffin-embed-
ded human tissues were retrieved from the archive of
the Department of Pathology (Spedali Civili di Bres-
cia, Brescia, Italy). Anti-PGE
2
(rabbit polyclonal, 1 : 700
overnight, Biorbyt) was revealed using DakoEnvision +
System-HRP Labelled Polymer Anti-Rabbit and DAB after
antigen retrieval (thermostatic bath, TRIS-EDTA buffer, pH
9.0). Characterization of PGE
2
positive cells was performed
by double immunohistochemistry usingCD11c (mouse, clone
5D11, 1 : 50, Leica Microsystems) and visualized using Mach
4 MR-AP (Biocare Medical, CA), followed by Ferangi Blue
(Biocare Medical) as chromogen. Immunostained sections
were photographed using the DP-70 Olympus digital camera
mounted on the Olympus BX60 microscope.
2.8. Statistical Analysis. Statistical significance between the
experimental groupswas determined using one-wayANOVA
withDunnett’s post hoc test (GraphPad Prism version 4.00 for
Windows, GraphPad Software).
3. Results and Discussion
3.1. The Stimulation of TLR4 and TLR7-8 Induces PGE2
in Human DCs. Human DCs were stimulated with TLR-
specific ligands and analysed for the release of PGE
2
. Fig-
ure 1(a) shows that, in addition to LPS (TLR4 ligand),
only R848 (TLR7 and TLR8 ligand, from now on TLR7-8)
could stimulate the secretion of PGE
2
. The ligands for
TLR1/2 (PAM
3
CSK
4
), TLR2/6 (FSL-1), TLR3 (Poly I:C), TLR5
(Flagellin), TLR7 (Imiquimod), and TLR9 (CpG) were by
contrast ineffective. Thus, we asked whether these receptors
were expressed and functional in DCs. Figure 1(b) shows that
DCs express all TLR mRNAs, exception made for TLR9.
While the absence of TLR9 in myeloid DCs is generally
recognized, the expression of TLR7 is controversial [14–16].
However, since TLR1–8 ligands activated DCs to produce
CXCL8 (Figure 1(c)), we concluded that these receptors were
indeed expressed and functional in our experimental setting.
CpG was excluded from further analysis because of the lack
of its cognate receptor.
Previous works have compared TLR ligands for their
capability to induce differential cytokine production by
human DCs [17–22]. To our knowledge, our study is the
first to investigate eicosanoid production induced by different
TLRs and to highlight so far oversight differential ability
of TLR ligands to induce the release of PGE
2
in human
DCs.
3.2. MAPKs and NF-𝜅B Are Key Downstream Signalling
Molecules for PGE2 Production. LPS, a ligand inducing robust
PGE
2
secretion over a vast range of concentrations (Fig-
ure 2(a)), was used to further investigate the signalling
pathways responsible for PGE
2
production in DCs. Since in
other experimental settings the regulation of PGE
2
involves
the activation of MAPKs and NF-𝜅B [3, 23, 24], DCs were
stimulated in the presence of specific MAPK inhibitors such
as U0126 (inhibitor of MAPK kinase), PD98059 (inhibitor of
extracellular-signal-regulated kinase 1/2-ERK1/2), SB203580
(inhibitor of MAPK p38), and, of the NF-𝜅B inhibitor,
BAY11-7082, which all significantly reduced the release of
PGE
2
(Figure 2(b)) when used at the lower concentration,
without affecting cell viability (not shown). Of note, the same
signalling pathways also regulated the induction ofCOX2, the
rate-limiting enzyme for PGE
2
synthesis (Figure 2(c)).
These results confirm that, in human DCs, the release of
PGE
2
depends on the activation of the MAPK and NF-𝜅B
pathways.
3.3. TLR Ligands Differentially Activate MAPKs and NF-𝜅B in
Human DCs. In order to clarify the molecular mechanisms
hindering the release of PGE
2
by inactive TLR ligands,
we analysed how different TLR stimulation impacted the
activation of MAPKs and NF-𝜅B. Figure 3 shows that all
ligands induced ERK1/2 phosphorylation, although at differ-
ent extent. However only LPS, R848, PAM
3
CSK
4
, and FSL-
1 also induced p38 phosphorylation and NF-𝜅B p65 nuclear
translocation, while Poly I:C, Flagellin, and Imiquimod did
not. Finally, TLR2 ligands failed to phosphorylate MSK1, a
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Figure 1: TLR4 and TLR7-8 stimulation induce the secretion of PGE
2
by DCs. ((a) and (c)) DCs at day 6 of culture were stimulated with
PAM
3
CSK
4
(100 ng/mL), FSL-1 (100 ng/mL), Poly I:C (25𝜇g/mL), LPS (100 ng/mL), Flagellin (100 ng/mL), Imiquimod (5𝜇g/mL), R848
(5𝜇g/mL), and CpG (6 𝜇g/mL). After 24 h, supernatants were collected and the production of PGE
2
(a) and CXCL8 (c) was evaluated by
EIA or ELISA, respectively. Results are expressed as mean ± SEM (𝑛 = 4); ∗𝑃 < 0.05 compared with respective controls by one-way ANOVA
with Dunnett’s post hoc test. (b) mRNA from DCs at day 6 of culture was extracted to analyse the expression of TLRs. Data are expressed as
mean ± SEM (𝑛 = 3).
kinase downstream ERK and p38 MAPK that was described
to play a role in PGE
2
production [25, 26]. Similar activation
patterns were also detected at 15 and 60 minutes after
stimulation (not shown).
Such striking differences in the activation of MAPKs and
NF-𝜅B are interesting because, according to the literature, all
TLR agonists are expected to converge on these pathways to
exert their biological effects [27, 28].Our results underline the
importance to confirm and refine previous findings, obtained
in model cell lines and often by transfection, in primary cells
expressing TLRs at physiological levels.
Of particular interest was the difference in the acti-
vation induced by Imiquimod and R848, both in terms
of intracellular signalling and in terms of PGE
2
secretion.
TLR7 and TLR8 both recognize ssRNA, are similar in
sequence and localization, and, together with TLR9, form
an evolutionary related TLR subfamily sharing common
signalling pathways responsible for antiviral responses [28].
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Figure 2:The release of PGE
2
by DCs depends on the activation of theMAPK and NF-𝜅B pathways. (a) DCs were stimulated with increasing
concentrations of LPS for 24 h and PGE
2
production was quantified by EIA. Data are expressed as mean ± SEM (𝑛 = 3); ∗𝑃 < 0.05 by
one-way ANOVA with Dunnett’s post hoc test. (b) DCs were pretreated for 1 h with the indicated doses of U0126, PD98059, SB203580, or
BAY-11-7082 and then stimulated with LPS (100 ng/mL) for 24 h. The production of PGE
2
was evaluated in cell-free supernatants by EIA.
Results are expressed as mean ± SEM (𝑛 = 3); ∗𝑃 < 0.05 by one-way ANOVA with Dunnett’s post hoc test. (c) DCs were treated as in (b),
using 1 𝜇M of each inhibitor. The expression of COX2 and 𝛽-actin was determined by Western blot. One representative fluorogram out of
three and its densitometric analysis are shown.
The differences we have observed may thus merely depend
on the limited expression of TLR7, which would explain
the lower PGE
2
secretion induced by Imiquimod. However,
Imiquimod phosphorylated ERK1/2 at levels that were com-
parable to, if not exceeding, those induced by R848, despite
the fact that it failed to activate other signalling molecules.
This may unveil a qualitative rather than a quantitative
difference between the signalling pathways activated by TLR7
and TLR8, as suggested by other authors [20, 29]. In addition,
we hypothesized that R848, by concomitantly triggering
TLR7 and TLR8, may activate a synergy between the two
signalling pathways. This issue represent an interesting area
of investigation that will be intensively pursued.
3.4. TLR3, TLR5, and TLR7 Stimulation Fail to Induce
COX2,While TLR1/2 and TLR2/6 Stimulation Fail toMobilize
AA. We next examined how the TLR-activated signalling
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Figure 3: TLRs differentially activate the MAPK and NF-𝜅B pathways. DCs were stimulated with TLR agonists as indicated in Figure 1
for 30min. After cell lysis, extracts were blotted against phospho-p38, phospho-ERK1/2, and phospho-MSK1. Nuclear extracts were blotted
against NF-𝜅B p65. 𝛽-actin and Lamin B represent loading controls for total and nuclear proteins, respectively. The image depicts results
obtained in one representative donor out of three.
pathways could differentially affect COX2 activation. Because
COX2 activity directly correlates with protein levels [3],
Western blot analysis was used to address this issue. Fig-
ure 4(a) clearly shows that Poly I:C, Flagellin, and Imiquimod
failed to induce COX2 accumulation, which fully explains
the lack of PGE
2
secretion and also confirms that NF-
𝜅B activation is critical for COX2 expression [23, 24]. By
contrast, PAM
3
CSK
4
and FSL-1 were as effective as LPS or
R848 in COX2 induction, suggesting that these ligands lack
in downstream steps of PGE
2
synthesis.
Thus,we analysed the activation of cPLA
2
, the other PGE
2
key-producing enzyme. Within minutes, cPLA
2
is regulated
by phosphorylation [30]. We found that only LPS and R848
induced significant cPLA
2
phosphorylation at 30 minutes
after stimulation (Figure 4(b)). Based on the observations
in Figure 3, it is tempting to speculate that, in our system,
cPLA
2
phosphorylation may depend on MSK1 activation,
as previously demonstrated in human fibroblasts stimulated
with IL-1𝛽 [25, 26].
Consistent with inefficient cPLA
2
phosphorylation,
PAM
3
CSK
4
and FSL-1 did not induce AA release as
compared to LPS and R848 (Figure 4(c)), suggesting that
TLR1/2 and TLR2/6 stimulation may fail to induce PGE
2
secretion because of the unavailability of AA, the substrate
for COX2 enzyme. According to this hypothesis, the
administration of exogenous AA (Figure 4(d), black bars)
restored the production of PGE
2
by PAM
3
CSK
4
and FSL-1,
but not by Poly I:C, Flagellin, and Imiquimod due to their
inability to accumulate COX2.
Altogether, these results identify AA and COX2 accumu-
lation as the PGE
2
-limiting checkpoints downstreamTLR1/2-
2/6 and TLR3-5-7 stimulation, respectively.
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Figure 4: Lack of AA mobilization blocks the release of PGE
2
upon TLR1/2 and TLR2/6 stimulation. (a) DCs were stimulated with TLR
agonists for 24 h. The expression of COX2 and 𝛽-actin was determined by Western blot. Fluorogram from one out of 3 representative
donors and its densitometric analysis are shown. (b) DCs were stimulated with TLR agonists for 30min and the phosphorylation of cPLA
2
was determined by immunoblot. One out of 3 representative donors and its densitometric analysis are shown. (c) DCs were labelled with
0.125 𝜇Ci/mL [14C] AA overnight and then stimulated with the indicated TLR ligands for 3 h. The results are expressed as the means ± SEM
(𝑛 = 3) of the percentage of [14C] AA release on the total radioactivity recovered from each stimulation; ∗𝑃 < 0.05 by one-way ANOVA with
Dunnett’s post hoc test. (d) DCs were incubated with TLR ligands in the presence (black bars) or absence (white bars) of 10𝜇M AA. After
24 h, supernatants were collected and the production of PGE
2
was evaluated by EIA. Results are expressed as mean ± SEM (𝑛 = 3); ∗𝑃 < 0.05
by one-way ANOVA with Dunnett’s post hoc test.
3.5. Human DCs Produce PGE2 In Vivo. Despite the fact that
DCs are very well known PGE
2
targets [2], their potential
as prostaglandin sources in humans is less investigated and
remains under debate. In fact, using in vitro differentiated
DCs as a model, it was described that human DCs either
could [31, 32] or could not produce PGE
2
[33]. In addition, the
strict ligand selectivity we have demonstrated so far raises the
question of how primary DCs may respond to real pathogens
in terms of PGE
2
production.
To shed light on the possible role of DCs as PGE
2
-
producing cells in vivo, we stimulated primary, circulating
mDCs with TLR4 ligands. Figure 5(a) shows that these
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Figure 5: CD11c+ cells produce PGE
2
in human inflamed lymph nodes. (a) Circulating mDCs were stimulated with LPS (100 ng/mL) or
heat-killed E. coli (1 : 10mDC/bacteria ratio). After 24 h, supernatants were collected and the production of PGE
2
was evaluated by EIA. Data
are expressed as mean ± SEM (𝑛 = 3); ∗𝑃 < 0.05 by one-way ANOVA with Dunnett’s post hoc test. (b) Sections from FFPE reactive lymph
nodes were stained as indicated. Cytoplasmic PGE
2
is observed in a fraction of CD11c+ cells. Representative double positive cells are indicated
by arrow heads. Sections are counterstained with Meyer’s haematoxylin. Original magnifications: 400x (scale bar 50𝜇m).
cells respond to TLR4 stimulation releasing amounts of
PGE
2
that are much higher than those observed for their
in vitro-derived counterparts. This is in line with previous
observations that IL-4 used to generate DCs may hinder
the activity of cPLA
2
[33]. Finally, we performed double
immunohistochemistry stainings on human inflamed lymph
nodes, showing a fraction of CD11c+ cells expressing PGE
2
in
their cytoplasm (Figure 5(b)).
These results conform that primary DCs can actively
secrete PGE
2
in inflammatory conditions in vivo.
The net effect of the simultaneous stimulation of dif-
ferent TLRs and also of other classes of innate immune
receptors by whole microorganisms remains to be elucidated.
However, it is plausible that pathogens expressing molecu-
lar patterns activating TLR4 and TLR7-8 may be stronger
PGE
2
inducers. Thus, the pathogen-dictated modulation
of the release of PGE
2
may represent a novel mechanism
through which DCs shape the immune and inflammatory
responses.
4. Conclusion
In the present paper, we demonstrate a differential abil-
ity of TLR ligands to induce the release of PGE
2
and
provide a detailed description of the mechanisms gov-
erning TLR-mediated eicosanoid production in human
DCs. A schematic representation of our findings is out-
lined in Figure 6. Briefly, only the stimulation of TLR4
and TLR7-8 could activate ERK1/2, p38, MSK1, and NF-
𝜅B and induce PGE
2
. By contrast, the PGE
2
-limiting
checkpoints downstream TLR1/2-2/6 and TLR3-5-7 stim-
ulation were identified in AA and COX2 accumulation,
respectively.
Our results also highlighted so far oversight differ-
ences in MAPK and NF-𝜅B activation by TLR ligands.
These divergences may have come to light because, con-
trary to works performed in transfected cell lines, our
system consisted of primary cells expressing a physi-
ologic repertoire of receptors and intracellular adaptor
molecules.
Finally, by demonstrating the expression of PGE
2
by
CD11c+ cells in human inflamed lymph nodes, this study
further expands our knowledge on the complex role of DCs
in the regulation of immune responses.
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Figure 6: Mechanisms of PGE
2
production by TLR family members. TLR4 triggering induces the transcription of COX2 via NF-𝜅B and
MAPK p38 and ERK1/2 as well as cPLA
2
phosphorylation and AA mobilization, presumably via MAPK and/or MSK1, which is in turn
converted into PGE
2
by COX2 and released into the medium. Similar mechanisms of action can be envisaged when TLR7 and 8 are
concomitantly activated by R848. TLR3, TLR5, and TLR7 fail to activate NF-𝜅B and selected MAPKs, thus hindering the transcription of
COX2. By contrast, TLR1/2 and TLR2/6 cause no PGE
2
release because of inefficient cPLA
2
phosphorylation and AA mobilization, which
may correlate with their inability to phosphorylate MSK1.
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